DDInter740 DDInter1214
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Midostaurin
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Midostaurin
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Midostaurin
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Tamoxifen
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Midostaurin
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tamoxifen
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Midostaurin
Flecainide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Midostaurin
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Midostaurin
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Afatinib
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Midostaurin
Flecainide {u} (Compound) upregulates {v} (Gene) AARS
AARS {u} (Gene) is upregulated by {v} (Compound) Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Midostaurin
Flecainide {u} (Compound) upregulates {v} (Gene) GARS
GARS {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may lead to a major life threatening interaction when taken with {v} Midostaurin
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Midostaurin
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tamoxifen (Compound) and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Flecainide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Afatinib (Compound) and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Flecainide (Compound) upregulates AARS (Gene) and AARS (Gene) is upregulated by Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Flecainide (Compound) upregulates GARS (Gene) and GARS (Gene) is upregulated by Vemurafenib (Compound) and Vemurafenib may lead to a major life threatening interaction when taken with Midostaurin